DDAVP in the treatment of diabetes insipidus: a clinical study.
In three cases of established cranial diabetes insipidus, the effectiveness of the new vasopressin analogue 1-desamino-8-D-arginine vasopressin (DDAVP) in controlling diabetes insipidus is demonstrated. A single dose of 20 micrograms of DDAVP given intranasally had an antidiuretic action from 16 to 24 hours in the three cases, and 10 micrograms given twice daily intranasally was effective in controlling the diabetes insipidus with no side effects. All the patients preferred this form of therapy to their previous treatment.
D000328:Adult; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D003864:Depression, Chemical; D003919:Diabetes Insipidus / Q000188:drug therapy* / Q000503:physiopathology; D004231:Diuresis / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014667:Vasopressins / Q000031:analogs & derivatives*
D014667:Vasopressins; D003894:Deamino Arginine Vasopressin